Skip to content

Feasibility study for the development of a sero-correlate of protection against invasive Group B Streptococcus disease (the iGBS study)

Feasibility study for the development of a sero-correlate of protection against invasive Group B Streptococcus disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN49326091
Enrollment
4000
Registered
2018-07-09
Start date
2018-07-02
Completion date
Unknown
Last updated
2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Invasive infant disease caused by Group B Streptococcus Infections and Infestations

Interventions

The trialists will establish maternal delivery/infant cord serum collection from 5 maternity units (around 4000 women) and test the feasibility of their strategies. They will collect a small sample of

Sponsors

St George's University Hospitals NHS Foundation Trust
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Pregnant 2. = 18 years of age 3. Delivering at one of the selected hospitals 4. Consented to participate during the study period

Exclusion criteria

Exclusion criteria: Does not meet the inclusion criteria

Design outcomes

Primary

MeasureTime frame
The feasibility of collecting serum at delivery (either maternal or cord or both) from a large cohort of pregnant women, assessed using: 1. Enrolment rate (the rate (proportion) of eligible women who are willing to participate in the delivery blood collection study) 2. Maternal and/or cord blood collection rate 3. Key clinical exclusion data (gestation at birth, receipt of IAP in labour (yes/no), type of IAP (list), time between administration of IAP and delivery (in hours) collection rate) 4. Infant iGBS surveillance consent rate

Secondary

MeasureTime frame
In the sub-study the following are assessed at delivery: 1. Rectovaginal swab study consent rate 2. Rectovaginal swab collection rate 3. Rectovaginal GBS colonisation rate 4. Rectovaginal GBS CPS serotype-specific colonisation rates In the sub-study where samples of maternal/cord blood and rectovaginal swabs are available, the following are assessed at delivery: 1. Infant blood sample study consent rate 2. Infant Guthrie card consent rate 3. Infant Guthrie card collection rate

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 20, 2026